Core Viewpoint - New Gold (NGD) has received a Zacks Rank 2 (Buy) upgrade, indicating a positive trend in earnings estimates, which is a significant factor influencing stock prices [1][3]. Earnings Estimates and Stock Price Impact - The Zacks rating system emphasizes the correlation between changes in earnings estimates and stock price movements, particularly influenced by institutional investors [4]. - Rising earnings estimates for New Gold suggest an improvement in the company's underlying business, which could lead to higher stock prices as investors respond positively [5]. Zacks Rank System - The Zacks Rank system classifies stocks based on earnings estimate revisions, with a strong historical performance, particularly for Zacks Rank 1 stocks, which have averaged a +25% annual return since 1988 [7]. - New Gold's upgrade to Zacks Rank 2 places it in the top 20% of Zacks-covered stocks, indicating a strong potential for market-beating returns in the near term [10]. Earnings Estimate Revisions for New Gold - For the fiscal year ending December 2025, New Gold is expected to earn $0.42 per share, consistent with the previous year's figure [8]. - Over the past three months, the Zacks Consensus Estimate for New Gold has increased by 83.7%, reflecting a significant upward revision in earnings expectations [8].

HudBay Minerals (HBM) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.The Zacks rating relies solely on a company's changing earnings picture. It tracks EPS estimates for the current and following years from the sell-side analysts covering the stock through a consensus measure -- the Zacks Consensus Estimate.Since a changing earnings p ...

Core Viewpoint - AMN Healthcare Services (AMN) has been upgraded to a Zacks Rank 2 (Buy), indicating a positive outlook on its earnings estimates, which is a significant factor influencing stock prices [1][4]. Earnings Estimates and Ratings - The Zacks rating system is based on changes in earnings estimates, which are tracked through the Zacks Consensus Estimate for EPS from sell-side analysts [2]. - The Zacks rating upgrade for AMN reflects an optimistic earnings outlook, likely leading to increased buying pressure and a rise in stock price [4][6]. Impact of Institutional Investors - Changes in a company's future earnings potential, as indicated by earnings estimate revisions, are strongly correlated with stock price movements, largely due to institutional investors adjusting their valuations based on these estimates [5]. - An increase in earnings estimates typically results in higher fair value for a stock, prompting institutional investors to buy or sell accordingly, which influences stock price movements [5]. Earnings Estimate Revisions for AMN - For the fiscal year ending December 2025, AMN is expected to earn $1.08 per share, unchanged from the previous year, but the Zacks Consensus Estimate has increased by 9.7% over the past three months [9]. Zacks Rank System - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with a strong historical performance, where Zacks Rank 1 stocks have generated an average annual return of +25% since 1988 [8]. - AMN's upgrade to Zacks Rank 2 places it in the top 20% of Zacks-covered stocks, indicating a strong potential for market-beating returns in the near term [11].

Voya Financial (VOYA) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by the system.Since a ch ...

Core Viewpoint - Gold Fields (GFI) has been upgraded to a Zacks Rank 1 (Strong Buy), indicating a positive outlook based on rising earnings estimates, which significantly influence stock prices [1][3][10] Earnings Estimates and Stock Price Impact - The Zacks rating system emphasizes the importance of earnings estimate revisions, which are strongly correlated with near-term stock price movements [4][6] - Institutional investors often adjust their valuations based on changes in earnings estimates, leading to significant buying or selling actions that affect stock prices [4] Recent Performance of Gold Fields - For the fiscal year ending December 2025, Gold Fields is expected to earn $2.57 per share, unchanged from the previous year, but the Zacks Consensus Estimate has increased by 47.7% over the past three months [8] Zacks Rank System - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with Zacks Rank 1 stocks historically generating an average annual return of +25% since 1988 [7] - Gold Fields' upgrade to Zacks Rank 1 places it in the top 5% of Zacks-covered stocks, suggesting potential for market-beating returns in the near term [10]

Core Viewpoint - Hagerty, Inc. (HGTY) has been upgraded to a Zacks Rank 1 (Strong Buy), indicating a positive outlook based on rising earnings estimates, which are crucial for stock price movements [1][4][6]. Earnings Estimates and Ratings - The Zacks rating system is primarily driven by changes in a company's earnings picture, with the Zacks Consensus Estimate reflecting EPS estimates from sell-side analysts [2][3]. - The recent upgrade for Hagerty signifies an improvement in its earnings outlook, likely leading to increased buying pressure and a rise in stock price [4][6]. Impact of Earnings Estimate Revisions - Changes in future earnings potential, as indicated by earnings estimate revisions, are strongly correlated with near-term stock price movements, influenced by institutional investors [5][7]. - For Hagerty, a 5.4% increase in the Zacks Consensus Estimate over the past three months suggests a positive trend in earnings expectations [9]. Zacks Rank System - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with Zacks Rank 1 stocks historically generating an average annual return of +25% since 1988 [8]. - The upgrade of Hagerty to Zacks Rank 1 places it in the top 5% of Zacks-covered stocks, indicating a strong potential for market-beating returns in the near term [10][11].

Core Viewpoint - Kinross Gold (KGC) has been upgraded to a Zacks Rank 2 (Buy), indicating a positive outlook based on rising earnings estimates, which significantly influence stock prices [1][2][4]. Earnings Estimates and Stock Performance - The Zacks rating system emphasizes the correlation between changes in earnings estimates and stock price movements, making it a valuable tool for investors [2][3][5]. - Kinross Gold's earnings estimates have seen a substantial increase, with a 48.5% rise in the Zacks Consensus Estimate over the past three months for the fiscal year ending December 2025, projected at $1.15 per share [7]. Zacks Rank System - The Zacks Rank system categorizes stocks into five groups based on earnings estimates, with a proven track record of Zacks Rank 1 stocks averaging a +25% annual return since 1988 [6]. - Kinross Gold's upgrade to Zacks Rank 2 places it in the top 20% of Zacks-covered stocks, suggesting a strong potential for market-beating returns in the near term [9].

Company Overview - Exelixis (EXEL) shares increased by 7.4% to close at $43.37, supported by high trading volume, contrasting with a 4.8% decline over the past four weeks [1] - The company announced that the late-stage STELLAR-303 study met one of its dual primary endpoints, showing a statistically significant improvement in overall survival for patients treated with zanzalintinib in combination with Tecentriq compared to regorafenib [2] - The consensus EPS estimate for Exelixis is $0.63 for the upcoming quarter, reflecting a year-over-year decrease of 25%, with expected revenues of $571.08 million, down 10.4% from the previous year [3] Earnings and Estimates - The consensus EPS estimate for Exelixis has been revised 0.8% higher in the last 30 days, indicating a positive trend that may lead to price appreciation [4] - Exelixis holds a Zacks Rank of 2 (Buy), suggesting favorable market sentiment [4] Industry Context - Exelixis operates within the Zacks Medical - Biomedical and Genetics industry, where Cartesian Therapeutics, Inc. (RNAC) also competes, having closed 0.7% higher at $9.83 [4] - Cartesian Therapeutics has a consensus EPS estimate of -$0.77, representing a significant year-over-year change of -242.6%, and currently holds a Zacks Rank of 3 (Hold) [5]

Group 1 - XOMA Royalty (XOMA) shares increased by 9% to close at $26.22, with trading volume significantly higher than usual, contrasting with a 3.2% loss over the past four weeks [1][2] - The rise in stock price is linked to positive investor sentiment regarding XOMA's growing portfolio of assets, which includes rights to future payments from therapeutic candidates [2] - The company reported strong financial results for Q1 2025, with expectations of a quarterly loss of $0.12 per share, reflecting a year-over-year change of +57.1%, and revenues projected at $9.43 million, down 15% from the previous year [3] Group 2 - The consensus EPS estimate for XOMA has been revised 33.9% higher in the last 30 days, indicating a positive trend that typically leads to price appreciation [4] - XOMA Royalty holds a Zacks Rank of 3 (Hold) and is part of the Zacks Medical - Biomedical and Genetics industry [5] - Another company in the same industry, Compugen (CGEN), saw a 0.6% decline in its stock price, with a consensus EPS estimate remaining unchanged at -$0.07, representing a year-over-year change of -250% [5][6]

Company Overview - Nektar Therapeutics (NKTR) shares increased by 12.1% to close at $9.54, following a significant volume of trading, contrasting with a 13.2% loss over the previous four weeks [1] - The rise in stock price is attributed to growing investor optimism regarding the phase IIb REZOLVE-AD study of rezpegaldesleukin for moderate-to-severe atopic dermatitis [1] Financial Expectations - Nektar is projected to report a quarterly loss of $2.53 per share, reflecting a year-over-year increase of 32.5% [2] - Expected revenues for the upcoming report are $10.78 million, which is a decrease of 54.1% compared to the same quarter last year [2] Earnings Estimate Revisions - The consensus EPS estimate for Nektar has been revised 10.5% higher in the last 30 days, indicating a positive trend that typically correlates with stock price appreciation [3] - Monitoring Nektar's stock is advised to see if the recent price increase can sustain and lead to further strength [3] Industry Context - Nektar operates within the Zacks Medical - Drugs industry, which includes other companies such as Indivior PLC (INDV) [4] - Indivior's stock closed 0.4% lower at $13.95, but has seen a return of 24.4% over the past month [4] - Indivior's consensus EPS estimate remains unchanged at $0.25, representing a decline of 43.2% from the previous year [5]